Corrigendum to ‘Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins’ [Nutr Metab Cardiovasc Dis. 2022 Sep;32(9):2255–2263]

The authors regret to inform that the published table 2 should be amended. In fact, additional values derived from a previous version of the paper were erroneously left in the fourth column. Furthermore, typos are present in legend and footnote. The correct text is in the following section.Tabled 1Table 2: Changes in estimated mean levels of continuous endpoints during the follow-up by treatment and within- and between-group comparisons (T6 vs. T0) (post-PSM ITT population).Change inVisitGla-300Deg-100Gla-300 vs. Deg-100Estimated mean and 95% CIEstimated mean difference from T0 and 95% CIWithin group p-value∗Between groups difference (estimated mean and 95% CI)Estimated mean difference from T0 and 95% CIWithin group p-value∗Between groups difference (estimated mean and 95% CI)Between group p-value∗∗HbA1c (%)T08.71 (8.59; 8.83)––8.70 (8.58; 8.82)––––T68.13 (8.02; 8.24)−0.58 (−0.69;-0.47)<0.00018.20 (8.08; 8.32)−0.50 (−0.61;-0.39)<0.0001−0.08 (−0.24; 0.08)0.16FBG (mg/dl)T0186.62 (180.74; 192.50)––186.91 (181.03; 192.79)––––T6165.44 (159.40; 171.48)−21.18 (−28.07;-14.29)<0.0001168.58 (162.46; 174.70)−18.34 (−25.31;-11.37)<0.0001−2.84 (−12.64; 6.96)0.57Body weight (Kg)T082.73 (81.29; 84.17)––83.05 (81.61; 84.49)––––T682.98 (81.54; 84.42)0.25 (−0.07; 0.57)0.1383.19 (81.75; 84.63)0.14 (−0.19; 0.47)0.420.11 (−0.35; 0.57)0.64Total daily insulin dose (U)T057.55 (55.08; 60.02)––58.50 (56.03; 60.97)––––T658.74 (56.06; 61.42)1.19 (−0.01; 2.39)0.05259.76 (57.07; 62.45)1.26 (0.05; 2.47)0.04−0.07 (−1.77; 1.63)0.93Total daily insulin dose (U/Kg)T00.70 (0.67; 0.73)––0.70 (0.67; 0.73)––−0.00 (−0.02; 0.02)0.70T60.71 (0.68; 0.74)0.01 (−0.00; 0.02)0.270.72 (0.69; 0.75)0.01 (−0.00; 0.02)0.11––Daily basal insulin dose (U)T024.49 (23.46; 25.52)––24.65 (23.62; 25.68)––––T625.83 (24.68; 26.98)1.34 (0.79; 1.89)<0.000126.41 (25.26; 27.56)1.76 (1.20; 2.32)<0.0001−0.42 (−1.20; 0.36)0.30Daily basal insulin dose (U/Kg)T00.29 (0.28; 0.30)––0.30 (0.29; 0.31)––––T60.31 (0.30; 0.32)0.01 (0.00; 0.02)0.00010.32 (0.31; 0.33)0.02 (0.01; 0.03)<0.0001−0.01 (−0.02; 0.00)0.06Total daily short-acting insulin dose (U)T028.89 (27.07; 30.71)––30.44 (28.62; 32.26)––––T632.76 (30.92; 34.60)3.87 (2.51; 5.23)<0.000133.28 (31.44; 35.12)2.83 (1.46; 4.20)<0.00011.03 (−0.90; 2.96)0.29Total daily short-acting insulin dose (U/Kg)T00.40 (0.38; 0.42)––0.41 (0.39; 0.43)––––T60.40 (0.38; 0.42)−0.00 (−0.01; 0.01)0.400.40 (0.38; 0.42)−0.01 (−0.02; 0.00)0.110.00 (−0.02; 0.02)0.58Statistically significant p-values (p < 0.05) are in bold.∗Paired t-test derived from linear mixed models for repeated measurements.∗∗Unpaired t-test derived from linear mixed models for repeated measurements. Open table in a new tab Statistically significant p-values (p < 0.05) are in bold. ∗Paired t-test derived from linear mixed models for repeated measurements. ∗∗Unpaired t-test derived from linear mixed models for repeated measurements. The authors would like to apologise for any inconvenience caused. Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulinsNutrition, Metabolism and Cardiovascular DiseasesVol. 32Issue 9PreviewData on second generation basal insulin (2BI) in people with type 2 diabetes (T2D) generated by clinical trials still need confirmation in real-world clinical settings. This study aimed at assessing the comparative effectiveness of 2BI [Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (Deg-100)] in T2D Italian patients switching from first generation basal insulins (1BI). Full-Text PDF Open Access